share_log

和黃醫藥：自願性公告－和黃醫藥宣佈繼FRUZAQLA (呋喹替尼/ fruquintinib) 在歐洲首次納入醫保將獲得來自武田的里程碑付款

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA (fruquintinib)

HKEX ·  Dec 13 08:00

Summary by Moomoo AI

和黃醫藥宣佈將收到來自合作夥伴武田的1千萬美元里程碑付款，因FRUZAQLA®（呋喹替尼）在西班牙獲得首個歐洲公共醫療保障範圍的建議。FRUZAQLA®於2024年6月在歐盟獲批，用於治療轉移性結直腸癌，是歐洲超過十年來首個獲批的此類口服創新靶向療法。此次納入醫保是在歐洲提高患者可及性的重要一步，體現了和黃醫藥與武田致力於解決轉移性結直腸癌患者需求的共同承諾。FRUZAQLA®的批准主要基於FRESCO-2國際多中心III期研究的結果，該研究數據已發表於《柳葉刀》。目前，FRUZAQLA®已在美國、歐盟、瑞士、加拿大、日本、英國等多個國家獲批。結直腸癌是歐洲第二大癌症相關死亡原因，FRUZAQLA®作為一種選擇性VEGFR抑制劑，為患者提供了新的治療選擇。和黃醫藥將繼續與武田合作，推進FRUZAQLA®在全球的開發和商業化。
和黃醫藥宣佈將收到來自合作夥伴武田的1千萬美元里程碑付款，因FRUZAQLA®（呋喹替尼）在西班牙獲得首個歐洲公共醫療保障範圍的建議。FRUZAQLA®於2024年6月在歐盟獲批，用於治療轉移性結直腸癌，是歐洲超過十年來首個獲批的此類口服創新靶向療法。此次納入醫保是在歐洲提高患者可及性的重要一步，體現了和黃醫藥與武田致力於解決轉移性結直腸癌患者需求的共同承諾。FRUZAQLA®的批准主要基於FRESCO-2國際多中心III期研究的結果，該研究數據已發表於《柳葉刀》。目前，FRUZAQLA®已在美國、歐盟、瑞士、加拿大、日本、英國等多個國家獲批。結直腸癌是歐洲第二大癌症相關死亡原因，FRUZAQLA®作為一種選擇性VEGFR抑制劑，為患者提供了新的治療選擇。和黃醫藥將繼續與武田合作，推進FRUZAQLA®在全球的開發和商業化。
Hutchmed (China) announced that it will receive a milestone payment of 10 million USD from its partner Takeda, due to the recommendation for public healthcare coverage for FRUZAQLA® (furmonertinib) in Spain. FRUZAQLA® is expected to be approved in the EU in June 2024 for the treatment of metastatic colorectal cancer, making it the first innovative oral targeted therapy of its kind approved in Europe in over a decade.The inclusion in the healthcare system is an important step in improving patient accessibility in Europe and reflects Hutchmed's and Takeda's shared commitment to addressing the needs of metastatic colorectal cancer patients. The approval of FRUZAQLA® is mainly based on the results of the FRESCO-2 international multicenter phase III study, the data...Show More
Hutchmed (China) announced that it will receive a milestone payment of 10 million USD from its partner Takeda, due to the recommendation for public healthcare coverage for FRUZAQLA® (furmonertinib) in Spain. FRUZAQLA® is expected to be approved in the EU in June 2024 for the treatment of metastatic colorectal cancer, making it the first innovative oral targeted therapy of its kind approved in Europe in over a decade.The inclusion in the healthcare system is an important step in improving patient accessibility in Europe and reflects Hutchmed's and Takeda's shared commitment to addressing the needs of metastatic colorectal cancer patients. The approval of FRUZAQLA® is mainly based on the results of the FRESCO-2 international multicenter phase III study, the data of which has been published in The Lancet. Currently, FRUZAQLA® has been approved in several countries including the USA, EU, Swiss Franc, Canada, Japan, and the United Kingdom.Colorectal cancer is the second leading cause of cancer-related deaths in Europe, and FRUZAQLA® provides new treatment options as a selective VEGFR inhibitor. Hutchmed will continue to collaborate with Takeda to advance the development and commercialization of FRUZAQLA® globally.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated